^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

IDH1 overexpression

i
Other names: HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble
Entrez ID:
Related biomarkers:
Twitter
Trials
3ms
Functional Disruption of TET2-Mediated Cytosine Oxidation in CAR-T Cells Using IDH1 Neomorph (ASH 2022)
Adoptive cell therapy through T cells with Chimeric Antigen Receptor (CAR) including Tisagenlecleucel and Axicabtagene Ciloleucel introduced a breakthrough in cancer immunotherapy against CLL and have risen as game changers in the cancer care scenario but still remain several challenges including durable remission and lack of expansion after infusion. This study therefore suggests that the functional disruption of TET2 via the overexpression of the IDH1 neomorph results in augmented memory function of CAR T cells with preservation of effector function. Our discovery introduced an alternative approach for functional TET2 disruption for CAR T cell improvement.
CAR T-Cell Therapy • IO biomarker
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CD8 (cluster of differentiation 8) • TET2 (Tet Methylcytosine Dioxygenase 2) • IFNG (Interferon, gamma) • CD27
|
IDH1 mutation • IDH1 R132H • IDH wild-type • IDH1 R132 • IDH1 overexpression
|
Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T)
4ms
IDH1 mutation activates mTOR signaling pathway, promotes cell proliferation and invasion in glioma cells. (PubMed, Mol Biol Rep)
Our results highlighted IDH1 mutation upregulate mTOR signaling pathway and promote cell proliferation, invasion and migration.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation • IDH1 R132H • MTOR mutation • IDH1 R132C • IDH wild-type • IDH1 R132 • IDH1 overexpression
6ms
Using AI-Based Evolutionary Algorithms to Elucidate Adult Brain Tumor (Glioma) Etiology Associated with IDH1 for Therapeutic Target Identification. (PubMed, Curr Issues Mol Biol)
Genes with mechanistic links to IDH1 were involved in brain neuronal development, cell proliferation, cytokinesis, and O-mannosylation as well as tumor suppression and anaplerosis. Results highlight metabolic vulnerabilities and therapeutic targets for use in future clinical trials.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH wild-type • IDH1 overexpression
11ms
IDH1 facilitates melanoma cell survival under metabolic stress (AACR 2022)
In addition, silencing IDH1 sensitized melanoma cells to temozolomide (TMZ), a DNA-alkylating agent, as indicated by a decrease in relative cell survival compared with controls. IDH1 plays a critical role in tumorigenesis and chemoresistance in melanoma. IDH1 plays a critical role in tumorigenesis and chemoresistance in melanoma. Our data show that IDH1 inhibition sensitizes melanoma cells to TMZ therapy. Our study suggests that IDH1 is a potential target in melanoma as a monotherapy or in combination with existing chemotherapies.
IO biomarker
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH wild-type • IDH1 overexpression
|
temozolomide
1year
Molecular characterization and preclinical development of novel small molecule inhibitor specific for wild-type IDH1 for ferroptosis induction in Glioblastoma (SNO 2021)
wt-IDH1i-13 is brain-penetrant, and similar to genetic ablation, reduces progression and extends the survival of wt-IDH1 high HGG bearing mice, alone and in combination with RT. These studies credential to wt-IDH1i-13 as a novel therapeutic modality for the treatment of wt-IDH1 gliomas.
Preclinical
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • GPX4 (Glutathione Peroxidase 4)
|
IDH1 overexpression